EUPRAXIA PHARMACEUTICALS INC. (EPRX) Form 6-K — Oct 22, 2026

$EPRXForm 6-KFiled Oct 22, 2026, 8:50 AM ET0001171843-26-006756Original filing

Eupraxia Pharmaceuticals announced management participation in several upcoming investor conferences, including the Craig Hallum Biotech Catalyst Conference, BIO-Europe, the Stifel 2026 Healthcare Conference, and the Jefferies Global Healthcare Conference in London. The company will also host a virtual Analyst Day on November 13, 2026, focused on EP-104GI, its Phase 1b/2 RESOLVE trial candidate for eosinophilic esophagitis using the Diffusphere drug-delivery platform.

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.